Sana Biotechnology (NASDAQ:SANA) Trading Down 3.8%

Sana Biotechnology, Inc. (NASDAQ:SANA) shares fell 3.8% during trading on Thursday . The stock traded as low as $7.89 and last traded at $7.95. 182,037 shares were traded during trading, a decline of 94% from the average session volume of 3,074,527 shares. The stock had previously closed at $8.26.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SANA. JMP Securities increased their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Sana Biotechnology in a report on Friday, March 1st.

Sana Biotechnology Stock Down 1.6 %

The business’s fifty day simple moving average is $8.97 and its two-hundred day simple moving average is $5.94.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. During the same quarter last year, the firm posted ($0.40) earnings per share. On average, equities research analysts predict that Sana Biotechnology, Inc. will post -1.02 earnings per share for the current year.

Insider Activity

In other news, Director Robert Nelsen bought 1,818,181 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average price of $5.50 per share, for a total transaction of $9,999,995.50. Following the transaction, the director now directly owns 12,446,022 shares of the company’s stock, valued at approximately $68,453,121. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 34.90% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Sana Biotechnology by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 9,797,084 shares of the company’s stock worth $39,972,000 after purchasing an additional 629,499 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Sana Biotechnology by 35.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 830,292 shares of the company’s stock valued at $3,388,000 after acquiring an additional 215,650 shares in the last quarter. American International Group Inc. increased its position in Sana Biotechnology by 2.5% in the 4th quarter. American International Group Inc. now owns 47,694 shares of the company’s stock valued at $195,000 after acquiring an additional 1,151 shares in the last quarter. Virtu Financial LLC increased its position in Sana Biotechnology by 59.6% in the 4th quarter. Virtu Financial LLC now owns 18,527 shares of the company’s stock valued at $76,000 after acquiring an additional 6,921 shares in the last quarter. Finally, Employees Retirement System of Texas acquired a new stake in Sana Biotechnology in the 4th quarter valued at about $53,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.